AMGN $53.56 target and Aranesp estimates lowered on CMS changes-MP@FBRC Friedman Billings lowered their US Aranesp sales estimates for 2007-2012 and their target to $52 from $55. They now see 2007 Aranesp sales of $2.14B, down from $2.34B and EPS of $4.22, down from $4.28. :theflyonthewall
Know how to make God laugh? Tell Her your plans ....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.